Predictive values of serum SAA and sNFL levels in elderly Alzheimer’s disease

doi:10.3877/cma.j.issn.2095-123X.2022.03.007

Abstract

Abstract:

Objective

To investigate the predictive values of serum amyloid A (SAA) and serum neurofilament light chain (sNFL) levels in elderly patients with Alzheimer’s disease (AD).

Methods

One hundred and forty-seven elderly patients with AD risk factors treated in Neurology Department of Bozhou People’s Hospital from May 2016 to May 2021 were selected as the study group, and 128 elderly healthy persons (with normal cognitive function) in the same period were selected as the control group, and the levels of SAA and sNFL were detected and compared. The patients in the study group were followed up to observe their progress to AD, and they were divided into progressive group and non progressive group, and the levels of SAA and sNFL were compared, and the predictive values of SAA and sNFL levels on elderly AD were analyzed by receiver operating characteristic (ROC) curve.

Results

The levels of SAA and sNFL in the study group were higher than those in the control group (P<0.05). Follow up for 1-5 (2.65±0.67) years, there were 39 cases of AD (progressive group) in 147 elderly patients, and the progress rate was 26.53%. The levels of SAA and sNFL in progressive group were higher than those in non progressive group (P<0.05). Of the 147 elderly patients, 8 patients were followed up after 5 years, and the cohort retention rate was 5.44%, and 3 cases progressed to AD and 5 cases did not progressed to AD after 5 years of follow-up among them. ROC results showed that the sensitivity of SAA and sNFL in combination prediction of AD was higher than that of single prediction (P<0.05), and the area under the curve was also higher than that of single prediction (P<0.05), but there was no significant difference between specificity and single prediction (P>0.05).

Conclusion

The SAA and sNFL levels in AD patients are higher than those in non AD patients, and they all have certain predictive value for AD, but the combined predictive value is higher.

Key words: Alzheimer’s disease, Serum amyloid A, Serum neurofilament light chain, Predictive value

Min Li, Yun Liu. Predictive values of serum SAA and sNFL levels in elderly Alzheimer’s disease[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(03): 157-161.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2022.03.007

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2022/V12/I03/157

Figures/Tables 4

References 21

[14]	Goeral K, Hauck A, Atkinson A, et al. Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants[J]. J Neurol, 2021, 268(7): 2570-2577.
[15]	管细红,黄文娟,鄢茵,等.迟发型阿尔茨海默病患者脑脊液神经丝轻链蛋白含量测定的meta分析[J].中国卫生统计, 2018, 35(1): 74-76.
[16]	吴纪霞,温振东,梁友宝,等.血清神经丝蛋白轻链对卒中后认知障碍的临床意义[J].蚌埠医学院学报, 2021, 46(9): 1187-1191.
[17]	刘聪辉,戈艳蕾,朱晓颖,等.血清MCP-1、SAA对于2型糖尿病伴OSAHS患者认知功能损伤的临床意义[J].中国老年学杂志, 2019, 39(9): 2096-2098.
[18]	Jakimovski D, Zivadinov R, Ramanthan M, et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study[J]. Mult Scler, 2020, 26(13): 1670-1681.
[19]	Iodice F, Cassano V, Rossini PM. Direct and indirect neurological, cognitive, and behavioral effects of COVID-19 on the healthy elderly, mild-cognitive-impairment, and Alzheimer’s disease populations[J]. Neurol Sci, 2021, 42(2): 455-465.
[20]	Jang S, Jang WY, Choi M, et al. Serum amyloid A1 is involved in amyloid plaque aggregation and memory decline in amyloid beta abundant condition[J]. Transgenic Res, 2019, 28(5-6): 499-508.
[21]	吴永明. LncRNA RP11-543N12.1与CDH13在老年阿尔茨海默病病人中的表达及其与炎性因子,认知功能的相关性[J].中西医结合心脑血管病杂志, 2021, 19(17): 3022-3025.
[1]	Lei B, Hou W, Zou W, et al. Longitudinal score prediction for Alzheimer's disease based on ensemble correntropy and spatial-temporal constraint[J]. Brain Imaging Behav, 2019, 13(1): 126-137.
[2]	De Buck M, Gouwy M, Wang JM, et al. Structure and expression of different serum amyloid a (SAA) variants and their concentration-dependent functions during host insults[J]. Curr Med Chem, 2016, 23(17): 1725-1755.
[3]	李真真,付爱双,戈艳蕾,等. 2型糖尿病伴OSAHS患者血清HCY、SAA水平与认知功能的关系研究[J].重庆医学, 2019, 48(5): 803-806.
[4]	Sutter R, Hert L, De Marchis GM, et al. Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without coronavirus disease 2019[J]. Ann Neurol, 2021, 89(3): 610-616.
[5]	吴纪霞,温振东,梁友宝,等.血清神经丝蛋白轻链对卒中后认知障碍的临床意义[J].蚌埠医学院学报, 2021, 46(9): 1187-1191.
[6]	薛慧萍,侯苹,李永男,等.记忆与执行筛查量表在鉴别轻度认知功能障碍与阿尔兹海默病中的作用[J].全科护理, 2019, 17(11): 1291-1294.
[7]	Nikolac Perkovic M, Videtic Paska A, Konjevod M, et al. Epigenetics of Alzheimer's disease[J]. Biomolecules, 2021, 11(2): 195.
[8]	Chen Y, Strickland MR, Soranno A, et al. Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis[J]. Neuron, 2021, 109(2): 205-221.
[9]	Chandra A, Dervenoulas G, Politis M, et al. Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment[J]. J Neurol, 2019, 266(6): 1293-1302.
[10]	王静,杜红兴.血管性痴呆和阿尔茨海默病血清炎症因子、临床生化指标的变化[J].中国医学创新, 2020, 17(9): 40-44.
[11]	戈艳蕾,刘聪辉,张嘉宾,等.慢性阻塞性肺疾病伴或不伴低氧血症患者外周血MCP-1, SAA蛋白及mRNA水平与认知功能损伤关系探讨[J].中国呼吸与危重监护杂志, 2018, 17(4): 327-330.
[12]	孔令霞,张林伟,张砚波. COPD患者血清8-iso-PGF-2α, MCP-1及SAA水平与认知功能的关系[J].国际医药卫生导报, 2020, 26(21): 3274-3278.
[13]	陈岩青,宫平,刘震,等. Saa3缺失改善阿尔茨海默病模型小鼠认知功能障碍和Tau蛋白病理进展[J].中国药科大学学报, 2021, 52(5): 586-595.

组别	例数	SAA（mmoL/L）	sNFL（pg/mL）
研究组	147	77.25（76.23，80.26）	52.55（45.40，63.52）
对照组	128	43.26（32.15，54.27）	31.24（28.51，34.26）
U值		12.036	10257
P值		<0.001	<0.001

组别	例数	SAA（mmoL/L）	sNFL（pg/mL）
研究组	147	77.25（76.23，80.26）	52.55（45.40，63.52）
对照组	128	43.26（32.15，54.27）	31.24（28.51，34.26）
U值		12.036	10257
P值		<0.001	<0.001

资料		进展组（n=39）	未进展组（n=108）	t/χ²/U值	P值
年龄（岁，Mean±SD）		68.46±11.82	68.14±12.24	0.141	0.888
性别[例（%）]				0.148	0.701
	男	21（53.85）	62（57.41）
	女	18（46.15）	46（42.59）
高血压[例（%）]		16（41.02）	32（29.62）	1.692	0.193
MMSE（分，Mean±SD）		17.33±3.11	20.48±2.59	6.163	<0.001
饮酒[例（%）]		14（35.89）	29（26.85）	1.133	0.287
SAA[mmoL/L，M（P₂₅，P₇₅）]		81.23（80.20，82.20）	76.98（76.12，77.70）	13.264	<0.001
sNFL[pg/mL，M（P₂₅，P₇₅）]		68.33（59.95，72.80）	48.22（43.92，55.04）	11.025	<0.001

资料		进展组（n=39）	未进展组（n=108）	t/χ²/U值	P值
年龄（岁，Mean±SD）		68.46±11.82	68.14±12.24	0.141	0.888
性别[例（%）]				0.148	0.701
	男	21（53.85）	62（57.41）
	女	18（46.15）	46（42.59）
高血压[例（%）]		16（41.02）	32（29.62）	1.692	0.193
MMSE（分，Mean±SD）		17.33±3.11	20.48±2.59	6.163	<0.001
饮酒[例（%）]		14（35.89）	29（26.85）	1.133	0.287
SAA[mmoL/L，M（P₂₅，P₇₅）]		81.23（80.20，82.20）	76.98（76.12，77.70）	13.264	<0.001
sNFL[pg/mL，M（P₂₅，P₇₅）]		68.33（59.95，72.80）	48.22（43.92，55.04）	11.025	<0.001

指标	cut-off值	灵敏度	特异度	AUC	95%CI
SAA	79.26 mmoL/L	31/39（79.49）	94/108（87.03）	0.845	0.776~0.900
sNFL	58.10 pg/mL	32/39（82.05）	90/108（83.33）	0.861	0.794~0.912
联合检测		38/39（97.44）	89/108（82.41）	0.949	0.900~0.978

Please choose a citation manager

Content to export